AI is about to change healthcare. These 110 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
To own HNI, you need to be comfortable with a mid-cap manufacturer whose story hinges on steady execution in office furniture and building products, incremental margin improvement, and disciplined capital allocation, including a long-running dividend. The latest news fits into that picture in two ways. First, the upcoming February 25, 2026 earnings call is the next clear catalyst, where investors will look for confirmation that earnings growth, cost savings from footprint consolidation, and integration of past moves are still on track. Second, the increase in institutional ownership and US$1.30 million of government contracts add credibility but do not materially change the near term fundamentals, given HNI’s multi billion dollar revenue base. The bigger swing factors remain demand trends, restructuring execution, and any surprises in guidance.
However, one operational decision could weigh more heavily on margins than many expect. HNI's shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.Explore 4 other fair value estimates on HNI - why the stock might be worth just $63.55!
Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.
Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com